Key Insights

Highlights

Success Rate

78% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

8.0%

6 terminated out of 75 trials

Success Rate

77.8%

-8.8% vs benchmark

Late-Stage Pipeline

3%

2 trials in Phase 3/4

Results Transparency

43%

9 of 21 completed with results

Key Signals

9 with results78% success

Data Visualizations

Phase Distribution

63Total
Not Applicable (23)
Early P 1 (4)
P 1 (21)
P 2 (13)
P 3 (2)

Trial Status

Completed21
Recruiting16
Unknown12
Active Not Recruiting9
Terminated6
Not Yet Recruiting5

Trial Success Rate

77.8%

Benchmark: 86.6%

Based on 21 completed trials

Clinical Trials (75)

Showing 20 of 20 trials
NCT05058846Active Not RecruitingPrimary

Pilot Study of Pancreatic Cancer Screening

NCT06172478Phase 2Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06168812Phase 2Active Not Recruiting

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

NCT07733427Not ApplicableNot Yet Recruiting

Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer

NCT07285044Phase 2Recruiting

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT06388967Recruiting

Pancreatic Cancer Detection Consortium

NCT02009449Phase 1Completed

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT06084013RecruitingPrimary

Use Of Indocyanine Green In Pancreas Surgery

NCT06995898Not ApplicableRecruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT07118176Phase 1Active Not Recruiting

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT07656376Phase 2Not Yet Recruiting

Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

NCT07650357Phase 1Not Yet Recruiting

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

NCT03711890Not ApplicableRecruitingPrimary

Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer

NCT06744595Not ApplicableEnrolling By InvitationPrimary

Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer

NCT06271291RecruitingPrimary

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

NCT06723236Phase 1Recruiting

A Study of MGC028 in Participants With Advanced Solid Tumors

NCT06799637Phase 1Recruiting

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

NCT06807437Phase 3RecruitingPrimary

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

NCT02676349Phase 2CompletedPrimary

Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

NCT04905082Not ApplicableActive Not Recruiting

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Scroll to load more

Research Network

Activity Timeline